Regis Doyonnas, PhD

Pfizer

Dr Regis Doyonnas obtained his PhD from the University Claude Bernard in Lyon (France) where he identified novel cytokines regulating hematopoiesis. He then builds expertise in hematopoietic and muscle stem cells by studying adhesion and transcription factors in Oxford (UK), Vancouver (Canada), and Stanford (USA). Since then, he has led the High Content Screening and High throughput flow cytometry facility at Pfizer, where his group supports all therapeutic areas in the early drug discovery portfolio. For the last 15 years at Pfizer, Regis has spearheaded phenotypic screening campaigns for multiple projects and established a cell painting platform to investigate novel small molecule Mechanism of Actions (MoA) in tumor cell lines and physiologically relevant human disease models.

Disclosure information not submitted.

Presentation(s):

• Lessons learned from Cell Painting screening and advancements in translational medicine with primary derived tumor models

  Tuesday, February 6, 2024
  2:00 PM – 3:00 PM EST